Mullerian inhibiting substance regulates androgen-induced gene expression and growth in prostate cancer cells through a nuclear factor-κB-dependent smad-independent mechanism

Molecular Endocrinology

Volumn 20, Issue 10, 2006, Pages 2382-2391

  Tran, Trinh T ^a   Segev, Dorry L ^a   Gupta, Vandana ^a   Kawakubo, Hirofumi ^a   Yeo, Giminna ^a   Donahoe, Patricia K ^a   Maheswaran, Shyamala ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MUELLERIAN INHIBITING FACTOR; PROSTATE SPECIFIC ANTIGEN; SMAD PROTEIN; TESTOSTERONE;

APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE; CELL STRAIN LNCAP; CELL SURVIVAL; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER;

ANDROGENS; ANTI-MULLERIAN HORMONE; APOPTOSIS; BLOTTING, NORTHERN; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; HUMANS; LUCIFERASES; MALE; NF-KAPPA B; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SMAD1 PROTEIN; TESTICULAR HORMONES;

EID: 33749338097     PISSN: 08888809     EISSN: 08888809     Source Type: Journal    
DOI: 10.1210/me.2005-0480     Document Type: Article

References (50)

1. Teixeira J, Maheswaran S, Donahoe PK 2001 Mullerian inhibiting substance: an instructive developmental hormone with diagnostic and possible therapeutic applications. Endocr Rev 22:657-674
2. Hudson PL, Dougas I, Donahoe PK, Cate RL, Epstein J, Pepinsky RB MacLaughlin DT 1990 An immunoassay to detect human mullerian inhibiting substance in males and females during normal development. J Clin Endocrinol Metab 70:16-22
3. Lee MM, Donahoe PK, Hasegawa T, Silverman B, Crist GB, Best S, Hasegawa Y, Noto RA, Schoenfeld D, MacLaughlin DT 1996 Mullerian inhibiting substance in humans: normal levels from infancy to adulthood. J Clin Endocrinol Metab 81:571-576
4. Baarends WM, van Helmond MJ, Post M, van der Schoot PJ, Hoogerbrugge JW, de Winter JP, Uilenbroek JT, Karels B, Wilming LG, Meijers JH, Themmen APN, Grootegoed JA 1994 A novel member of the transmembrane serine/threonine kinase receptor family is specifically expressed in the gonads and in mesenchymal cells adjacent to the mullerian duct. Development 120:189-197
5. di Clemente N, Wilson C, Faure E, Boussin L, Carmillo P, Tizard R, Picard JY, Vigier B, Josso N, Cate R 1994 Cloning, expression, and alternative splicing of the receptor for anti-Mullerian hormone. Mol Endocrinol 8:1006-1020
6. Teixeira J, He WW, Shah PC, Morikawa N, Lee MM, Catlin EA, Hudson PL, Wing J, Maclaughlin DT, Donahoe PK 1996 Developmental expression of a candidate mullerian inhibiting substance type II receptor. Endocrinology 137:160-165
7. Hoshiya Y, Gupta V, Segev DL, Hoshiya M, Carey JL, Sasur LM, Tran TT, Ha TU, Maheswaran S 2003 Mullerian Inhibiting Substance induces NFκB signaling in breast and prostate cancer cells. Mol Cell Endocrinol 211:43-49
8. Segev DL, Ha TU, Tran TT, Kenneally M, Harkin P, Jung M, MacLaughlin DT, Donahoe PK, Maheswaran S 2000 Mullerian inhibiting substance inhibits breast cancer cell growth through an NFκB-mediated pathway. J Biol Chem 275:28371-28379
9. Segev DL, Hoshiya Y, Hoshiya M, Tran TT, Carey JL, Stephen AE, MacLaughlin DT, Donahoe PK, Maheswaran S 2002 Mullerian-inhibiting substance regulates NF-κB signaling in the prostate in vitro and in vivo. Proc Natl Acad Sci USA 99:239-244
10. Segev DL, Hoshiya Y, Stephen AE, Hoshiya M, Tran TT, MacLaughlin DT, Donahoe PK, Maheswaran S 2001 Mullerian inhibiting substance regulates NFκB signaling and growth of mammary epithelial cells in vivo. J Biol Chem 276:26799-26806
11. Gouedard L, Chen YG, Thevenet L, Racine C, Borie S, Lamarre I, Josso N, Massague J, di Clemente N 2000 Engagement of bone morphogenetic protein type IB receptor and Smad1 signaling by anti-Mullerian hormone and its type II receptor. J Biol Chem 275:27973-27978
12. Clarke TR, Hoshiya Y, Yi SE, Liu X, Lyons KM, Donahoe PK 2001 Mullerian inhibiting substance signaling uses a bone morphogenetic protein (BMP)-like pathway mediated by ALK2 and induces SMAD6 expression. Mol Endocrinol 15:946-959
13. Jamin SP, Arango NA, Mishina Y, Hanks MC, Behringer RR 2002 Requirement of Bmpr1a for Mullerian duct regression during male sexual development. Nat Genet 32:408-410
14. Visser JA, Olaso R, Verhoef-Post M, Kramer P, Themmen AP, Ingraham HA 2001 The serine/threonine transmembrane receptor ALK2 mediates Mullerian inhibiting substance signaling. Mol Endocrinol 15:936-945
15. Attisano L, Wrana JL 2002 Signal transduction by the TGF-β superfamily. Science 296:1646-1647
16. Massague J 1998 TGF-β signal transduction. Annu Rev Biochem 67:753-791
17. Teixeira J, Fynn-Thompson E, Payne AH, Donahoe PK 1999 Mullerian-inhibiting substance regulates androgen synthesis at the transcriptional level. Endocrinology 140:4732-4738
18. Trbovich AM, Sluss PM, Laurich VM, O'Neill FH, MacLaughlin DT, Donahoe PK, Teixeira J 2001 Mullerian Inhibiting Substance lowers testosterone in luteinizing hormone-stimulated rodents. Proc Natl Acad Sci USA 98:3393-3397
19. Cancilla B, Jarred RA, Wang H, Mellor SL, Cunha GR, Risbridger GP 2001 Regulation of prostate branching morphogenesis by activin A and follistatin. Dev Biol 237:145-158
20. Ball EM, Risbridger GP 2001 Activins as regulators of branching morphogenesis. Dev Biol 238:1-12
21. Cunha GR, Foster B, Thomson A, Sugimura Y, Tanji N, Tsuji M, Terada N, Finch PW, Donjacour AA 1995 Growth factors as mediators of androgen action during the development of the male urogenital tract. World J Urol 13:264-276
22. Iwasaki S, Tsuruoka N, Hattori A, Sato M, Tsujimoto M, Kohno M 1995 Distribution and characterization of specific cellular binding proteins for bone morphogenetic protein-2. J Biol Chem 270:5476-5482
23. Risbridger GP, Thomas T, Gurusinghe CJ, McFarlane JR 1996 Inhibin-related proteins in rat prostate. J Endocrinol 149:93-99
24. van Schaik RH, Wierikx CD, Timmerman MA, Oomen MH, van Weerden WM, van der Kwast TH, van Steenbrugge GJ, de Jong FH 2000 Variations in activin receptor, inhibin/activin subunit and follistatin mRNAs in human prostate tumour tissues. Br J Cancer 82:112-117
25. Wikstrom P, Bergh A, Damber JE 2000 Transforming growth factor-β1 and prostate cancer. Scand J Urol Nephrol 34:85-94
26. Carlson BM 1999 Human embryology and developmental biology. 2nd ed. St. Louis, MO: Mosby
27. Allard S, Adin P, Gouedard L, di Clemente N, Josso N, Orgebin-Crist MC, Picard JY, Xavier F 2000 Molecular mechanisms of hormone-mediated Mullerian duct regression: involvement of β-catenin. Development 127:3349-3360
28. Roberts LM, Hirokawa Y, Nachtigal MW, Ingraham HA 1999 Paracrine-mediated apoptosis in reproductive tract development. Dev Biol 208:110-122
29. Baichwal VR, Baeuerle PA 1997 Activate NF-κB or die? Curr Biol 7:R94-R96
30. Barkett M, Gilmore TD 1999 Control of apoptosis by Rel/NF-κB transcription factors. Oncogene 18:6910-6924
31. Brown K, Gerstberger S, Carlson L, Franzoso G, Siebenlist U 1995 Control of IκB-α proteolysis by site-specific, signal-induced phosphorylation. Science 267:1485-1488
32. Syms AJ, Norris JS, Smith RG 1983 Androgen stimulated elevation in androgen receptor levels is inhibited by the synthetic glucocorticoid triamcinolone acetonide. Biochem Biophys Res Commun 116:1020-1025
33. Kurian MS, de la Cuesta RS, Waneck GL, MacLaughlin DT, Manganaro TF, Donahoe PK 1995 Cleavage of Mullerian inhibiting substance activates antiproliferative effects in vivo. Clin Cancer Res 1:343-349
34. Sugimura Y, Cunha GR, Donjacour AA 1986 Morphological and histological study of castration-induced degeneration and androgen-induced regeneration in the mouse prostate. Biol Reprod 34:973-983
35. Sugimura Y, Cunha GR, Donjacour AA, Bigsby RM, Brody JR 1986 Whole-mount autoradiography study of DNA synthetic activity during postnatal development and androgen-induced regeneration in the mouse prostate. Biol Reprod 34:985-995
36. Mitre AI, Castilho LN, Avarese de Figueiredo A, Arap S 2002 Persistent mullerian duct syndrome and prostate cancer. Urology 60:698
37. Behringer RR 1994 The in vivo roles of mullerian-inhibiting substance. Curr Top Dev Biol 29:171-187
38. Imbeaud S, Belville C, Messika-Zeitoun L, Rey R, di Clemente N, Josso N, Picard JY 1996 A 27 base-pair deletion of the anti-mullerian type II receptor gene is the most common cause of the persistent mullerian duct syndrome. Hum Mol Genet 5:1269-1277
39. Aggarwal BB, Takada Y 2005 Pro-apototic and antiapoptotic effects of tumor necrosis factor in tumor cells. Role of nuclear transcription factor NF-κB. Cancer Treat Res 126:103-127
40. Barrack ER 1997 TGFβ in prostate cancer: a growth inhibitor that can enhance tumorigenicity. Prostate 31:61-70
41. Bello-DeOcampo D, Tindall DJ 2003 TGF-βl/Smad signaling in prostate cancer. Curr Drug Targets 4:197-207
42. Dowling CR, Risbridger GP 2000 The role of inhibins and activins in prostate cancer pathogenesis. Endocr Relat Cancer 7:243-256
43. Koeneman KS, Yeung F, Chung LW 1999 Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate 39:246-261
44. Rowley DR 1998 What might a stromal response mean to prostate cancer progression? Cancer Metastasis Rev 17:411-419
45. Wikstrom P, Damber J, Bergh A 2001 Role of transforming growth factor-β1 in prostate cancer. Microsc Res Tech 52:411-419
46. Hoshiya Y, Gupta V, Kawakubo H, Brachtel E, Carey JL, Sasur L, Scott A, Donahoe PK, Maheswaran S 2003 Mullerian inhibiting substance promotes interferon-γ-induced gene expression and apoptosis in breast cancer cells. J Biol Chem 278:51703-51712
47. Ragin RC, Donahoe PK, Kenneally MK, Ahmad MF, MacLaughlin DT 1992 Human mullerian inhibiting substance: enhanced purification imparts biochemical stability and restores antiproliferative effects. Protein Expr Purif 3:236-245
48. Cleutjens KB, van der Korput HA, Ehren-van Eekelen CC, Sikes RA, Fasciana C, Chung LW, Trapman J 1997 A 6-kb promoter fragment mimics in transgenic mice the prostate-specific and androgen-regulated expression of the endogenous prostate-specific antigen gene in humans. Mol Endocrinol 11:1256-1265
49. Shang Y, Myers M, Brown M 2002 Formation of the androgen receptor transcription complex. Mol Cell 9:601-610
50. Ha TU, Segev DL, Barbie D, Masiakos PT, Tran TT, Dombkowski D, Glander M, Clarke TR, Lorenzo HK, Donahoe PK, Maheswaran S 2000 Mullerian inhibiting substance inhibits ovarian cell growth through an Rb-independent mechanism. J Biol Chem 275:37101-37109